Brief: Journey Medical Corporation Announces Completion Of Treatment Assessing Impact Of Dfd-29 (Minocycline Modified Release Capsules 40 Mg) On Microbial Flora In A Separate Phase 1 Clinical Trial
16/03/2023 13:13
March 16 (Reuters) - Journey Medical Corp DERM.O :
* JOURNEY MEDICAL CORPORATION ANNOUNCES COMPLETION OF
TREATMENT
ASSESSING IMPACT OF DFD-29 (MINOCYCLINE MODIFIED RELEASE
CAPSULES 40 MG) ON MICROBIAL FLORA IN A SEPARATE PHASE 1
CLINICAL TRIAL
* JOURNEY MEDICAL CORP - TOPLINE RESULTS EXPECTED IN FIRST
HALF OF
2023
Source text for Eikon: ID:nGNX6FYyx1
Further company coverage: DERM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Journey Medical
See all newsJourney Medical Corp expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
U.S. STOCKS ON THE MOVE-Five Below, Salesforce, IBM, Akamai Technologies